Prognostic factors in the treatment of polypoidal choroidal vasculopathy with conbercept: a post hoc analysis of the STAR study
Abstract Background A post hoc analysis of the STAR study, which was a 48-week, phase IV, multicenter randomized controlled multicenter clinical trial was performed. This study aims to identify the baseline factors associated with visual and anatomic changes over 48 weeks in the treatment of active...
Saved in:
| Main Authors: | Tsung-I. Wang, Jinfeng Qu, Ran Tang, Xuan Shi, Xin Ying, Ye Tao, Xiaoxin Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Eye and Vision |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40662-025-00441-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research status of clinicopathologic studies of polypoidal choroidal vasculopathy
by: LI Miaoling, et al.
Published: (2025-02-01) -
Polypoidal Choroidal Vasculopathy Treatment: Photodynamic Therapy, Anti-VEGF Monotherapy or Combination. Review of Clinical Studies
by: E. K. Pedanova, et al.
Published: (2019-06-01) -
A case of treating polypoidal choroidal vasculopathy subretinal fluid by subthreshold micropulse laser
by: Sarmad Mustafa Jafar, et al.
Published: (2024-12-01) -
Efficacy and Safety of Ophthalmic Steroids in the Management of Polypoidal Choroidal Vasculopathy: A Systematic Review
by: Adriono GA, et al.
Published: (2025-03-01) -
Full-Thickness Macular Hole Formation After Intravitreal Faricimab Injection for Polypoidal Choroidal Vasculopathy
by: Tavonvunchai F, et al.
Published: (2025-06-01)